Zidovudine paediatric formulation - Mylan Laboratories

Drug Profile

Zidovudine paediatric formulation - Mylan Laboratories

Latest Information Update: 20 Apr 2015

Price : $50

At a glance

  • Originator Matrix Laboratories
  • Developer Mylan Laboratories Limited
  • Class Antiretrovirals; Azides; Nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Oct 2011 Matrix Laboratories is now called Mylan Laboratories Inc.
  • 10 Mar 2011 Registered for HIV infections (prevention of mother-to-child transmission) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top